Literature DB >> 8102519

Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S 9788.

T Efferth1, T A Dunn, M Berlion, H Langenbahn, E W Pommerenke, M Volm.   

Abstract

In a panel of 14 primary cultures of human renal cell carcinomas the reversal of inherent multidrug-resistance by S 9788, a new triazinoaminopiperidine derivative, was analysed. In combination with doxorubicin S 9788 revealed an evident reversal of multidrug resistance in 12 cell cultures. Two cell cultures remained unaffected. An association between reversal and P-glycoprotein (P-170) expression suggests that S 9788 exerts its activity through P-glycoprotein.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8102519

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

1.  Investigation of multidrug resistance in cultured human renal cell carcinoma cells by 31P-NMR spectroscopy and treatment survival assays.

Authors:  N W Lutz; S E Franks; M H Frank; S Pomer; W E Hull
Journal:  MAGMA       Date:  2005-06-23       Impact factor: 2.310

2.  In vitro activity of S 9788 on a multidrug-resistant leukemic cell line and on normal hematopoietic cells-reversal of multidrug resistance by sera from phase I-treated patients.

Authors:  J Soudon; M Berlion; C Lucas; P Haddad; J P Bizzari; F Calvo
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

3.  Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S9788 in advanced colorectal and renal cell cancer.

Authors:  C J Punt; E E Voest; E Tueni; A T Van Oosterom; A Backx; P H De Mulder; B Hecquet; C Lucas; B Gerard; H Bleiberg
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.